ProPhase LabsPRPH -4.61% Market Cap is $1.28 Mil as of Jun. 25, 2026. The stock has 4 warning signs investors should review. Among 219 Medical Diagnostics & Research companies, ProPhase Labs ranks worse than 94.98% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). ProPhase Labs's share price for the quarter that ended in Dec. 2025 was $0.4475. ProPhase Labs's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 8.97 Mil. Therefore, ProPhase Labs's market cap for the quarter that ended in Dec. 2025 was $4.01 Mil.
ProPhase Labs's quarterly market cap
increased
from Jun. 2025 ($16.25 Mil) to Sep. 2025 ($19.02 Mil) but then
declined
from Sep. 2025 ($19.02 Mil) to Dec. 2025 ($4.01 Mil).
ProPhase Labs's annual market cap
declined
from Dec. 2023 ($81.59 Mil) to Dec. 2024 ($22.61 Mil) and
declined
from Dec. 2024 ($22.61 Mil) to Dec. 2025 ($4.01 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. ProPhase Labs's Enterprise Value for Today is $9.81 Mil.
ProPhase Labs (OTCPK:PRPH) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
ProPhase Labs Market Cap Related Terms
ProPhase Labs Market Cap Historical Data
* Premium members only.
The historical data trend for ProPhase Labs's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, ProPhase Labs's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Market Cap distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
ProPhase Labs's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProPhase Labs (PRPH) has a Market Cap of $1.28 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on ProPhase Labs and its competitors. According to the industry distribution chart, ProPhase Labs ranks #208 out of 219 companies in the Medical Diagnostics & Research industry, placing it in the top 95%.
Is ProPhase Labs' Market Cap too high?
ProPhase Labs' current Market Cap is $1.28 Mil. The Medical Diagnostics & Research industry median Market Cap is 57.30. ProPhase Labs' value of $1.28 Mil is 97.8% below this industry median. Based on the distribution chart, ProPhase Labs ranks #208 out of 219 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does ProPhase Labs' Market Cap compare to NSTM and IDTA?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #208 out of 219 companies for Market Cap. This places ProPhase Labs in the lower half of its industry. The industry median Market Cap is 57.30. ProPhase Labs' value of $1.28 Mil is 97.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 57.30, based on 219 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ProPhase Labs's current Market Cap of $1.28 Mil is 97.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on ProPhase Labs and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 57.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current Market Cap is $1.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.65, compared to a current price of $0.09 — trading 86% below its estimated fair value. The current Market Cap is $1.28 Mil and 97.8% below the Medical Diagnostics & Research industry median of 57.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Market Cap is $1.28 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your 